CN108779073A - 用于治疗癌症的组合物和方法 - Google Patents

用于治疗癌症的组合物和方法 Download PDF

Info

Publication number
CN108779073A
CN108779073A CN201680044840.5A CN201680044840A CN108779073A CN 108779073 A CN108779073 A CN 108779073A CN 201680044840 A CN201680044840 A CN 201680044840A CN 108779073 A CN108779073 A CN 108779073A
Authority
CN
China
Prior art keywords
pp2a
cancer
bases
inhibitor
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680044840.5A
Other languages
English (en)
Chinese (zh)
Inventor
G·那拉
M·奥米尔
D·麦奎德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xi Naishanyikan Medical College
Case Western Reserve University
Original Assignee
Xi Naishanyikan Medical College
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xi Naishanyikan Medical College, Case Western Reserve University filed Critical Xi Naishanyikan Medical College
Publication of CN108779073A publication Critical patent/CN108779073A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680044840.5A 2015-06-23 2016-06-23 用于治疗癌症的组合物和方法 Pending CN108779073A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183517P 2015-06-23 2015-06-23
US62/183,517 2015-06-23
PCT/US2016/039022 WO2016210134A1 (en) 2015-06-23 2016-06-23 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
CN108779073A true CN108779073A (zh) 2018-11-09

Family

ID=57586472

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680044840.5A Pending CN108779073A (zh) 2015-06-23 2016-06-23 用于治疗癌症的组合物和方法

Country Status (8)

Country Link
US (1) US10744141B2 (cg-RX-API-DMAC7.html)
EP (1) EP3313819A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018518522A (cg-RX-API-DMAC7.html)
CN (1) CN108779073A (cg-RX-API-DMAC7.html)
AU (1) AU2016281646A1 (cg-RX-API-DMAC7.html)
CA (1) CA2990835A1 (cg-RX-API-DMAC7.html)
IL (1) IL256523A (cg-RX-API-DMAC7.html)
WO (1) WO2016210134A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112816453A (zh) * 2021-02-09 2021-05-18 黑龙江大学 蛋白在预测药物性能上的应用
CN113616795A (zh) * 2021-08-31 2021-11-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN114984221A (zh) * 2022-05-25 2022-09-02 浙江大学 Pp2a及其激活剂在急性缺血性脑卒中制药、标记的应用
CN116421726A (zh) * 2023-04-14 2023-07-14 中国海洋大学 一种基于分子预测的靶向plk1纳米药物的开发方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995068B2 (en) 2015-09-24 2021-05-04 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
US12398103B2 (en) * 2020-03-20 2025-08-26 Atux Iskay Llc 3-diarylmethylenes and uses thereof
JP2023519931A (ja) * 2020-04-01 2023-05-15 エンジン バイオサイエンシズ プライベート リミテッド 癌を治療するための方法及び組成物
WO2022094615A1 (en) * 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
CN114617969B (zh) * 2020-12-14 2023-08-25 上海市肿瘤研究所 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
KR20230145089A (ko) * 2021-02-08 2023-10-17 랍타 테라퓨틱스 오와이 단백질 포스파타제 2a(pp2a)의 치환된 사이클릭 조절인자 및 이를 사용하는 방법
WO2025230951A1 (en) * 2024-04-29 2025-11-06 Icahn School Of Medicine At Mount Sinai Method of treating adenoid cystic carcinoma

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
WO2009117769A1 (en) * 2008-03-25 2009-10-01 Newcastle Innovation Limited Inhibition of c-kit cancers
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
US20120207767A1 (en) * 2006-03-13 2012-08-16 Osi Pharmaceuticals, Llc. Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors
US20120322792A1 (en) * 2011-01-11 2012-12-20 Mount Sinai School Of Medicine Method and Compositions for Treating Cancer and Related Methods
WO2013025882A2 (en) * 2011-08-16 2013-02-21 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
WO2014151955A1 (en) * 2013-03-15 2014-09-25 Life Technologies Corporation Prognostic assay for squamous cell lung carcinoma
US20150005263A1 (en) * 2011-12-22 2015-01-01 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
CN106458916A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
CN106458936A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 作为抗癌药的三环‑2‑氨基环烷醇衍生的磺酰胺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090020197A1 (en) * 2007-07-16 2009-01-22 Key Safety Systems, Inc. Gas generating compositions and airbag inflators
CA2758823A1 (en) * 2009-04-13 2010-10-21 The Ohio State University Research Foundation Protein phosphatase 2a-activating agents

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
US20120207767A1 (en) * 2006-03-13 2012-08-16 Osi Pharmaceuticals, Llc. Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
WO2009117769A1 (en) * 2008-03-25 2009-10-01 Newcastle Innovation Limited Inhibition of c-kit cancers
US20120322792A1 (en) * 2011-01-11 2012-12-20 Mount Sinai School Of Medicine Method and Compositions for Treating Cancer and Related Methods
WO2013025882A2 (en) * 2011-08-16 2013-02-21 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
US20150005263A1 (en) * 2011-12-22 2015-01-01 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer
WO2014151955A1 (en) * 2013-03-15 2014-09-25 Life Technologies Corporation Prognostic assay for squamous cell lung carcinoma
CN106458916A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 受限制的三环磺酰胺
CN106458936A (zh) * 2014-03-11 2017-02-22 西奈山伊坎医学院 作为抗癌药的三环‑2‑氨基环烷醇衍生的磺酰胺

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATRIN SPINNLER ET AL.: ""Role of Glycogen Synthase Kinase 3 (GSK-3) in innate immune response of human immature dendritic cells to Aspergillus fumigatus"", 《MEDICAL MYCOLOGY》 *
LING YAN ET AL.: ""PP2A Regulates the Pro-apoptotic Activity of FOXO1"", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112816453A (zh) * 2021-02-09 2021-05-18 黑龙江大学 蛋白在预测药物性能上的应用
CN113616795A (zh) * 2021-08-31 2021-11-09 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
CN114984221A (zh) * 2022-05-25 2022-09-02 浙江大学 Pp2a及其激活剂在急性缺血性脑卒中制药、标记的应用
CN116421726A (zh) * 2023-04-14 2023-07-14 中国海洋大学 一种基于分子预测的靶向plk1纳米药物的开发方法

Also Published As

Publication number Publication date
US10744141B2 (en) 2020-08-18
JP2018518522A (ja) 2018-07-12
CA2990835A1 (en) 2016-12-29
EP3313819A1 (en) 2018-05-02
IL256523A (en) 2018-02-28
US20180185382A1 (en) 2018-07-05
WO2016210134A1 (en) 2016-12-29
AU2016281646A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
CN108779073A (zh) 用于治疗癌症的组合物和方法
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP2022058398A (ja) Ｂｒａｆ－ｖ６００関連疾患の治療に使用するためのｐｌｘ－８３９４またはｐｌｘ－７９０４
JP6863970B2 (ja) ヘテロ環式化合物およびそれらの使用
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
US9718841B2 (en) Bicyclic pyrazolone compounds and methods of use
JP2021501142A (ja) キナーゼを調節する化合物の製剤
EP3585389A1 (en) Treatment of egfr-driven cancer with fewer side effects
RU2672910C9 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
TW202323253A (zh) 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CN108024540A (zh) 用于治疗癌症的方法
TW202233177A (zh) 治療黑色素瘤的藥物組合的用途
JP6526789B2 (ja) 組み合わせ療法
WO2024015855A1 (en) COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
TW202131917A (zh) 併用醫藥
US20190117663A1 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181109